Justin Hegel

Justin Hegel

Auto-generated profile, based on publicly available information

Justin Hegel

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2025 in Nature Communications
Verified
Journal Article
Open access
CWCaroline R. M. Wiggers
Caroline R. M. Wiggers
ECEugene Y. Cho
Eugene Y. Cho
MOMerve Ozdemir
Merve Ozdemir
GBGbolahan Bamgbose
Gbolahan Bamgbose
JHJustin Hegel
Justin Hegel
BKBirgit Knoechel
Birgit Knoechel
Changes in the immune microenvironment are frequent in cancers occurring in adult patients, yet our understanding of the pediatric cancer immune microenvironment and its clinical relevance is limited. We investigate the immune microenvironment in pediatric T cell acute lymphoblastic leukemia (T-ALL), using single-cell CITE-seq and immune repertoire analyses. We identify a T-ALL subgroup characterized by a remodeled immune microenvironment, which is associated with adverse clinical outcome in minimal residual disease low patients. This adverse immune landscape is dominated by the presence of a population of non-malignant CD4-CD8-TCRαβ T cells that interact with CXCL16 expressing non-classical monocytes. Leukemia cell intrinsic transcriptional rewiring in these patients is associated with activation of Rap1 signaling. Inhibiting Rap1 signaling results in increased sensitivity to the BCL2/BCL-XL inhibitor navitoclax. Our study provides insights into the immune microenvironment of pediatric hematologic malignancies, forming the basis for identifying potential (immuno) therapeutic targets and risk stratification for treatment.

30 July 2025 in Leukemia
Verified
Journal Article
Open access
PDF file
THTayla B. Heavican-Foral
Tayla B. Heavican-Foral
FKFelix Korell
Felix Korell
ISIrene Scarfò
Irene Scarfò
CWCaroline R. M. Wiggers
Caroline R. M. Wiggers
ABAllen Thayakumar B
Allen Thayakumar B
BKBirgit Knoechel
Birgit Knoechel
Chimeric antigen receptor (CAR) T cell therapy has not yet been realized for T-cell lymphomas (TCL), partially due to challenges in identifying tumor-specific antigens. We previously reported selective expression of CD37 on malignant T cells in a subset of TCL. Herein, we demonstrate CAR-37 T cells specifically target CD37-positive TCL in part by activating the intrinsic apoptotic pathway. To maximize therapeutic index, we identified selective/targetable BH3 dependences in individual TCL models and combined with CAR-37 T cells. We show that BH3 mimetics do not alter CD37 antigen binding capacity on TCL and have minimal effects on CAR-37 T-cell phenotype or function. In TCL models with dependence on MCL-1, combining CAR-37 T cells and the MCL-1 inhibitor AZD5991 increases anti-TCL response and prolongs survival of xenografted mice. These findings suggest that personalized selection of BH3 mimetic/CAR-T combinations could maximize the therapeutic index for patients with TCL and possibly other diseases.